App-Quantinova.ai

Longitudinal trajectories of self-reported subjective cognitive decline in relation to objective cognitive performance in a population-based cohort

Rebecca E Street - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

18F-florbetapir

Prognosis of patients with subjective cognitive decline in an unselected clinical sample

Tim Whitfield - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

- Multifactor mid-life risk for Alzheimer’s disease associated with alterations in navigation but not episodic memory: the PREVENT-Dementia study

Coco Newton - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

- Associations between semantic memory for proper names in story recall and CSF amyloid and tau in a cognitively unimpaired sample

Madeline R Hale - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

- Framework for disclosing AD biomarker results following cognitive assessment within a pragmatic, multi-country implementation evaluation

Tim MacLeod - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

- Speed of cognitive decline in biomarker stratified SCD subgroups

Frank Jessen - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Competing endogenous RNA network analysis of human prefrontal cortex in Alzheimer's disease

Ehsan Pishva - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

- DNA methylation profiling across brain regions in Huntington’s disease.

Greg Wheildon - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Huntington's disease

N/A

- A Role for Epigenetic Mechanisms in the Lewy Body Dementias

Jennifer L Imm - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

- An integrated systems-level analysis of the molecular changes resulting from systemic inflammation and amyloid-beta immunisation in Alzheimer’s disease

Lachlan Ford MacBean - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Systemic inflammation

AIP-001

- An Epigenome-wide association study of psychosis in Alzheimer's disease dorsolateral prefrontal cortex

Luke Stephen Weymouth - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

- Targeted bisulfite sequencing analysis of candidate genes associated with Alzheimer’s disease.

Greg Wheildon - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

N/A

- DNA methylation of mitochondrial DNA shows variation in human brain.

Greg Wheildon - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Lewy body dementia

N/A

- Investigating neurodegenerative heterogeneity in cognitively unimpaired A4 pre-randomization cohort

Neil P Oxtoby - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Risk factors for loneliness in family caregivers of people with dementia and enduring mental health conditions during the COVID-19 pandemic in Latin America

Tomas Leon - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Dementia

N/A

An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in Alzheimer’s disease

Yuanbing JIANG - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Genetic risk scores and dementia risk across different ethnic groups in UK Biobank

Naaheed Mukadam - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

Genetic mapping of APP and amyloid-β biology modulation by trisomy 21

Frances K Wiseman - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Down syndrome

N/A

Identification of novel genetic variants and biomarkers for cognitive decline in Alzheimer's disease

Muhammad Ali - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Increased white matter hyperintensity burden on MRI in autosomal dominant familial compared to young onset sporadic Alzheimer’s disease.

Alice Accorroni - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Filters

45280 Abstracts